Kenvue to Showcase 22 New Sets of Clinical Data at American Academy of Dermatology Association Meeting

Kenvue Inc. (“Kenvue”), the world’s largest pure-play consumer health company by revenue, will share new data demonstrating how its iconic brands are contributing to the advancement of everyday skin care at the American Academy of Dermatology (AAD) Association Annual Meeting, set for March 8-12 at the San Diego Convention Center in San Diego, California.

In findings from the 22 data sets detailing new Kenvue skin science research, industry experts will present evidence confirming the clinical effectiveness of Neutrogena and Aveeno formulations in moisturizing skin, improving skin barrier, protecting against UVA sun damage, and rapidly reducing facial acne. Kenvue will also offer hands-on experiences in exhibit-floor Booth 2511, featuring products that are household names, including those from the Neutrogena, Aveeno, NeoStrata, Lubriderm, BAND-AID Brand and Rogaine¹ portfolios.

“This is our first time presenting as Kenvue at the annual AAD meeting, allowing us a great opportunity to meet with leaders across dermatology and share our latest category-defining research that supports the value of our iconic brands as a part of everyday care,” said Adam Ricciardone², Head of R&D, Global Skin Health & Beauty and Head of R&D North America. “This evidence illustrates our ongoing commitment to delivering science-backed, care-forward experiences that are loved by consumers and recommended by healthcare professionals and experts.”

In six new clinical studies being presented at AAD, Kenvue investigators found that oat-containing moisturizers developed by Aveeno and Neutrogena scientists made the skin’s microbiome more resilient in a variety of populations. These include young children predisposed to eczema, women with dry skin, adults with mild to moderate eczema, and adults receiving immunobiological treatment for psoriasis.

Across these studies, findings showed that consumers enjoyed improved quality of life while using the moisturizing formulations — and, in many cases, for days afterwards or even longer. Specifically, product users experienced less itchiness, scaliness and self-consciousness about their appearance — or, in the case of the infants, improvements to the skin’s microbiome associated with a decreased risk of eczema.

Additional data to be presented at AAD demonstrates the benefits of Kenvue’s formulations for skin hydration, sun protection and acne control.

Studies presented will include:

Novel Natural Moisturizing Factor and Lipid-Containing Face Cream Induces Aquaporin-3 and Filaggrin Expression Associated with Barrier Improvements and Sustained Clinical Hydration in Extra-Dry Skin; Bernhardt KT, et al.